Search results
5 paź 2020 · Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing. October 5, 2020 at 9:00 AM EDT. PDF Version. Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”
3 cze 2020 · Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million to take an ex-AbbVie drug through phase 3.
5 paź 2020 · Aduro Biotech Inc. completed its reverse merger with privately held biotechnology company Chinook Therapeutics Inc. The resulting entity adopted the Chinook Therapeutics name and will begin trading on the Nasdaq Global Select Market under the KDNY trading symbol starting Oct. 6.
2 cze 2020 · Tue, Jun 2, 2020. – Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy.
30 mar 2015 · Novartis, a leader among companies using the immune system to fight cancer, is betting up to $750 million on a promising therapeutic approach from Aduro Biotech, widening its arsenal of potential...
Today, it announced the closing of its merger with Aduro Biotech, Inc. and $115 million private placement financing. The combined company, known as Chinook Therapeutics, will start trading under the ticker “KDNY” from October 6th.
15 kwi 2015 · Berkeley, CA's Aduro Biotech ($ADRO) banked $119 million in an upsized IPO with plans to hit the gas on its pipeline of treatments that use the body's immune system to battle cancer.
